test directorySearch Results
Click here to search again.
Test Name:
Rh Immunization Prevention Panel
- SBMF No:
28090 - Performance Lab Name:
Blood Bank Services - Test Mnemonic:
RHIG AP - ABN:
Not required - CPT Code:
86901; 86850; 90384 - LOINC Code:
10331-7; 890-4; 19066-0; 51784-7 - Test Includes:
Rh Blood Type only
Antibody Screen
Rh Immune Globulin - Also Known As:
Antepartem RhoGAM Panel - Also See:
35839 Obstetric Panel - Spec Type:
Whole blood - Spec Container:
Lavender top (EDTA) tube - Alt Spec Type:
Cells and serum - Alt Spec Container:
Red top (serum) tube - Pref Vol:
7.0 mL - Min Vol:
2.0 mL - Fasting:
No - Spec Collect:
Do not use gel-barrier tubes for specimen collection
Routine venipuncture - Spec Process:
Do not centrifuge
Do not remove serum or plasma from cells - Spec Store Transport:
Refrigerated - Spec Stability:
3 days (72 hours) refrigerated (2-8°C) - Spec Reject:
Hemolyzed sample - Spec Remarks:
Collect as close to one hour after delivery of all of the products of conception—this time is required for the rare, massive fetal-maternal hemorrhage to mix with the maternal circulation - Methodology:
See individual test listings - Use:
To identify female patients who should receive injections of Rh immune globulin (RHIG) during and/or immediately after their pregnancy
Administration of Rh immune globulin will to prevent the sensitization of an Rh negative mother to the D antigen of an Rh positive infant
It will also deter development of hemolytic disease of the newborn (HDN) in subsequent pregnancies - Clinical Significance:
The administration of a concentrated solution of D antibodies to Rh negative mothers who deliver Rh positive infants or whose pregnancies are terminated early prevents immunization of the mother to the D antigen. A standard dose of 300.0 µg Rho Immune Globulin (RhIG) will neutralize up to 15.0 mL of Rh positive packed red cells or 30.0 mL of fetal whole blood.
Administration of Rh immune globulin (RHIG) at 28 weeks of pregnancy prevents sensitization of Rh negative mothers caused by undetected fetal-maternal bleeds in the third trimester. At this time, the patient is screened for candidacy with tests for D and unexpected antibodies. If a patient has had a miscarriage or terminated a pregnancy at less than 12 weeks she must be screened for candidacy with tests for D and unexpected antibodies. In addition, patients who miscarry or terminate a pregnancy at more than 12 weeks must be screened for fetal-maternal bleed. - Reference Range:
Rh immune globulin is indicated for Rh negative women during or immediately after pregnancy who have not been immunized to the D antigen. - Day Run:
Mon-Fri - Time Run:
10:00 pm - Time Reported:
10:00 am next day if neg - Test Type:
OBSTETRIC-NEONATAL
